<DOC>
	<DOCNO>NCT00999414</DOCNO>
	<brief_summary>This compassionate use , open-label , IND study purpose provide carfilzomib patient relapse resistant refractory multiple myeloma .</brief_summary>
	<brief_title>UARK 2009-32 Compassionate Use Study Carfilzomib</brief_title>
	<detailed_description>The protocol design relapse refractory multiple myeloma patient . A maximum 30 patient may treat protocol . Since compassionate use study investigational agent , size determine agreement manufacturer carfilzomib . Therefore , time period enrollment accrual number limit N=30 .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>Participants must histologically document multiple myeloma relapse resistant stem cell transplantation , conventional therapy fail contraindicated Serum creatinine &lt; 3.0 mg/dL OR calculate creatinine clearance &gt; 15 mL/min calculate measured clearance â‰¥15 mL/min ANC &gt; 1000/mm3 ( may support growth factor ) Platelet count &gt; 30,000/mm3 ( may receive transfusion ) Female participant childbearing potential agree use dual method contraception duration study Male participant agree use barrier method contraception sexually active female childbearing potential Patients must sign IRBapproved write informed consent form demonstrate willingness meet followup schedule study procedure obligation Active infection require systemic treatment Requires concomitant use approve investigative anticancer therapeutic treatment activity multiple myeloma , dexamethasone Concomitant use investigative agent ( e.g. , antibiotic antiemetic ) Pregnant breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>MM</keyword>
</DOC>